GlassScriptPhysician profile
Felipe Sarda
NPI 1689789679
$747.77
in general payments reported to CMS, 2019-2025
9 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.55 · 2020: $60.22 · 2021: $40.75 · 2022: $81.43 · 2023: $155 · 2024: $223 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $210.24 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $164.50 | 2020-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Ironshore Pharmaceuticals INC. | $122.05 | 2019-2024 | |
| Genentech USA, INC. | $69.30 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $65.62 | 2025 | Jornay Pm |
| Pfizer INC. | $38.20 | 2020-2025 | |
| Tris Pharma INC | $35.52 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $28.00 | 2021-2022 | |
| Sanofi Pasteur INC. | $14.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Sarda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.